Grifols
- Market cap
- 5.10B
- P/E (TTM)i
- 10.15
- P/Bi
- 0.82
- EPSi
- 0.66
- Div yieldi
- 3.71%
- 52W posi
- 22%
Anonymous reader poll. Unscientific, not investment advice.
About Grifols
Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. It operates through the following segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma Segment includes all activities related with products deriving from human plasma for therapeutic use. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols i Roig in 1909 and is headquartered in Barcelona, Spain.
- Founded
- 1909
- CEO
- Mr. Jose Ignacio Abia Buenache
- Employees
- 25,247
- Headquarters
- Barcelona, Catalonia, Spain
- Fiscal year end
- 12-31
- Website
- grifols.com
Company profile
- Exchange
- US
- Symbol
- GRFS
- Market-cap rank
- #2138
- Listing date
- 1970-01-01
- Market cap
- 5.10B
- Float cap
- 3.14B
- Shares out
- 680.58M
- Float shares
- 418.22M
Sectors & themes
Quote time 2026-10-08 08:17:15 · For reference only, not investment advice and not tailored to your situation.